XOMA Corp. regulatory update

XOMA received three U.S. Patents, two of which relate to the Berkeley, Calif., company's Neuprex bactericidal/permeability-increasing protein (BPI).

Patent No. 5,466,580 covers methods for quantifying BPI levels in blood. XOMA is using the assay to analyze plasma samples from patients enrolled in its Neuprex Phase III trials. ...